Article Sidebar
Views pdf: 53
EVALUATE RESPONSE AND SAFETY OF CONCURRENT CHEMORADIOTHERAPY ON THE TREATMENT OF STAGE IIIB NON-SMALL CELL LUNG CANCER AT NATIONAL LUNG HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the response and safety of concurrent chemoradiotherapy in the treatment of stage IIIB non-small cell lung cancer (NSCLC) at the National Lung Hospital. Methods: A descriptive study was conducted on 66 patients with stage IIIB NSCLC who received concurrent chemoradiotherapy at the National Lung Hospital. Key variables included response rate and treatment-related adverse events affecting hematologic, liver, and renal function. Results: The overall response rate was 81.8%, with a complete response rate of 9.1% and a partial response rate of 72.7%. Adverse events were primarily mild hematologic effects (78.8%), and no severe liver or kidney toxicity was observed. Conclusion: Concurrent chemoradiotherapy is an effective treatment option for stage IIIB NSCLC, demonstrating high response rates and manageable safety profiles.
Article Details
Keywords
Stage IIIB non-small cell lung cancer, concurrent chemoradiotherapy, treatment response, adverse events, National Lung Hospital
References
2. Toàn, B.C., et al., Nghiên cứu đánh giá hiệu quả điều trị trong ung thư phổi không tế bào nhỏ bằng hóa - xạ trị đồng thời, in Tạp chí Y học thực hành. 2013. p. 47-52.
3. Radzikowska, E., P. Głaz, and K. Roszkowski, Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20561 cases. Annals of Oncology, 2002. 13(7): p. 1087-1093.
4. Fu, J.B., et al., Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest, 2005. 127(3): p. 768-777.
5. Albain, K.S., et al., Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. The Lancet, 2009. 374(9687): p. 379-386.
6. Toàn, B.C. and N.V. Long, Đáp ứng điều trị và thời gian sống thêm của ung thư phổi không tế bào nhỏ giai đoạn III theo phác đồ hóa-xạ trị đồng thời. Nghiên cứu y học, 2012. 15: p. 162-168.
7. Ohe, Y., et al., Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A). Cancer Sci, 2003. 94(8): p. 729-34.
8. Anh, L.T., Đặc điểm lâm sàng và điều trị của 1158 bệnh nhân ung thư phổi tại Trung tâm ung bướu Chợ Rẫy. Tạp chí Y học thực hành, 2013. 878: p. 20-22.